Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 104
Filtrer
1.
Toxicology ; 441: 152531, 2020 08.
Article de Anglais | MEDLINE | ID: mdl-32593706

RÉSUMÉ

Gene-regulatory networks reconstruction has become a very popular approach in applied biology to infer and dissect functional interactions of Transcription Factors (TFs) driving a defined phenotypic state, termed as Master Regulators (MRs). In the present work, cutting-edge bioinformatic methods were applied to re-analyze experimental data on leukemia cells (human myelogenous leukemia cell line THP-1 and acute myeloid leukemia MOLM-13 cells) treated for 6 h with two different Ribosome-Inactivating Proteins (RIPs), namely Shiga toxin type 1 (400 ng/mL) produced by Escherichia coli strains and the plant toxin stenodactylin (60 ng/mL), purified from the caudex of Adenia stenodactyla Harms. This analysis allowed us to identify the common early transcriptional response to 28S rRNA damage based on gene-regulatory network inference and Master Regulator Analysis (MRA). Both toxins induce a common response at 6 h which involves inflammatory mediators triggered by AP-1 family transcriptional factors and ATF3 in leukemia cells. We describe for the first time the involvement of MAFF, KLF2 and KLF6 in regulating RIP-induced apoptotic cell death, while receptor-mediated downstream signaling through ANXA1 and TLR4 is suggested for both toxins.


Sujet(s)
Réseaux de régulation génique/effets des médicaments et des substances chimiques , Leucémies/métabolisme , Protéines inactivant les ribosomes/pharmacologie , Lignée cellulaire tumorale , Régulation de l'expression des gènes dans la leucémie/effets des médicaments et des substances chimiques , Humains , Lectines/pharmacologie , Protéines membranaires/effets des médicaments et des substances chimiques , Protéines membranaires/métabolisme , N-Glycosyl hydrolases/pharmacologie , Shiga-toxine-1/pharmacologie , Facteurs de transcription/métabolisme
2.
Sci Rep ; 7(1): 10164, 2017 08 31.
Article de Anglais | MEDLINE | ID: mdl-28860505

RÉSUMÉ

Phage-derived lysins can hydrolyse bacterial cell walls and show great potential for combating Gram-positive pathogens. In this study, the potential of LysEF-P10, a new lysin derived from a isolated Enterococcus faecalis phage EF-P10, as an alternative treatment for multidrug-resistant E. faecalis infections, was studied. LysEF-P10 shares only 61% amino acid identity with its closest homologues. Four proteins were expressed: LysEF-P10, the cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domain (LysEF-P10C), the putative binding domain (LysEF-P10B), and a fusion recombination protein (LysEF-P10B-green fluorescent protein). Only LysEF-P10 showed highly efficient, broad-spectrum bactericidal activity against E. faecalis. Several key functional residues, including the Cys-His-Asn triplet and the calcium-binding site, were confirmed using 3D structure prediction, BLAST and mutation analys. We also found that calcium can switch LysEF-P10 between its active and inactive states and that LysEF-P10B is responsible for binding E. faecalis cells. A single administration of LysEF-P10 (5 µg) was sufficient to protect mice against lethal vancomycin-resistant Enterococcus faecalis (VREF) infection, and LysEF-P10-specific antibody did not affect its bactericidal activity or treatment effect. Moreover, LysEF-P10 reduced the number of Enterococcus colonies and alleviated the gut microbiota imbalance caused by VREF. These results indicate that LysEF-P10 might be an alternative treatment for multidrug-resistant E. faecalis infections.


Sujet(s)
Bactériophages/génétique , Multirésistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Enterococcus faecalis/virologie , Infections bactériennes à Gram positif/prévention et contrôle , N-Glycosyl hydrolases/administration et posologie , N-Glycosyl hydrolases/composition chimique , Animaux , Bactériophages/enzymologie , Bactériophages/isolement et purification , Sites de fixation , Modèles animaux de maladie humaine , Enterococcus faecalis/effets des médicaments et des substances chimiques , Femelle , Humains , Souris , Tests de sensibilité microbienne , Viabilité microbienne/effets des médicaments et des substances chimiques , Modèles moléculaires , Mutation , N-Glycosyl hydrolases/génétique , N-Glycosyl hydrolases/pharmacologie , Conformation des protéines , Similitude de séquences d'acides aminés , Protéines virales/administration et posologie , Protéines virales/composition chimique , Protéines virales/génétique , Protéines virales/pharmacologie
3.
Protein Expr Purif ; 130: 129-136, 2017 02.
Article de Anglais | MEDLINE | ID: mdl-27773761

RÉSUMÉ

The nucleoside hydrolase gene from Leishmania donovani was cloned and expressed in Escherichia coli as a full length 36-kDa protein (LdNH36). Following lysis and extraction, the protein was purified by anion exchange and gel filtration chromatography. The purified protein had a molecular mass of approximately 36-kDa and was confirmed to be >99% pure. Using a nucleoside hydrolase assay, the protein was found to exhibit a Km of 741 ± 246 µM. Protein integrity was confirmed by lithium dodecyl sulfate polyacrylamide gel electrophoresis (LDS-PAGE), mass spectrometry (MS), and enzymatic assay. Analysis of antibody levels from immunized mice indicated that LdNH36 alone or in a stable emulsion with the Toll-like receptor-4 ligand glucopyranosyl lipid adjuvant (GLA-SE) as immunostimulant induced high levels of antigen-specific IgG antibodies. The cellular immune response indicated a Th1 response in mice immunized with LdNH36, but only when formulated with GLA-SE. Mice immunized with the LdNH36 antigen in combination with the GLA-SE adjuvant and challenged with Leishmania mexicana showed significant reductions (>20 fold) in parasite burden, confirming the protective efficacy of this vaccine candidate.


Sujet(s)
Immunogénicité des vaccins , Leishmania donovani , Vaccins antileishmaniose , Leishmaniose cutanée , N-Glycosyl hydrolases , Protéines de protozoaire , Animaux , Femelle , Leishmania donovani/enzymologie , Leishmania donovani/génétique , Leishmania donovani/immunologie , Vaccins antileishmaniose/biosynthèse , Vaccins antileishmaniose/immunologie , Vaccins antileishmaniose/isolement et purification , Vaccins antileishmaniose/pharmacocinétique , Leishmaniose cutanée/immunologie , Leishmaniose cutanée/prévention et contrôle , Souris , Souris de lignée BALB C , N-Glycosyl hydrolases/biosynthèse , N-Glycosyl hydrolases/immunologie , N-Glycosyl hydrolases/isolement et purification , N-Glycosyl hydrolases/pharmacologie , Protéines de protozoaire/biosynthèse , Protéines de protozoaire/immunologie , Protéines de protozoaire/isolement et purification , Protéines de protozoaire/pharmacologie , Protéines recombinantes/biosynthèse , Protéines recombinantes/immunologie , Protéines recombinantes/isolement et purification , Protéines recombinantes/pharmacologie
4.
Toxins (Basel) ; 8(6)2016 06 10.
Article de Anglais | MEDLINE | ID: mdl-27294959

RÉSUMÉ

Endoglin (CD105) is an accessory component of the TGF-ß receptor complex, which is expressed in a number of tissues and over-expressed in the endothelial cells of tumor neovasculature. Targeting endoglin with immunotoxins containing type 2 ribosome-inactivating proteins has proved an effective tool to reduce blood supply to B16 mice tumor xenografts. We prepared anti-endoglin immunotoxin (IT)-containing recombinant musarmin 1 (single chain ribosome-inactivating proteins) linked to the mouse anti-human CD105 44G4 mouse monoclonal antibody via N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP). The immunotoxin specifically killed L929 fibroblast mouse cells transfected with the short form of human endoglin with IC50 values in the range of 5 × 10(-10) to 10(-9) M.


Sujet(s)
Endogline/immunologie , Immunotoxines/pharmacologie , N-Glycosyl hydrolases/pharmacologie , Animaux , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Humains , Souris
5.
Biotechnol Prog ; 31(6): 1487-93, 2015.
Article de Anglais | MEDLINE | ID: mdl-26399565

RÉSUMÉ

Bacteriolytic enzymes often possess a C-terminal binding domain that recognizes specific motifs on the bacterial surface and a catalytic domain that cleaves covalent linkages within the cell wall peptidoglycan. PlyPH, one such lytic enzyme of bacteriophage origin, has been reported to be highly effective against Bacillus anthracis, and can kill up to 99.99% of the viable bacteria. The bactericidal activity of this enzyme, however, appears to be strongly dependent on the age of the bacterial culture. Although highly bactericidal against cells in the early exponential phase, the enzyme is substantially less effective against stationary phase cells, thus limiting its application in real-world settings. We hypothesized that the binding domain of PlyPH may differ in affinity to cells in different Bacillus growth stages and may be primarily responsible for the age-restricted activity. We therefore employed an in silico approach to identify phage lysins differing in their specificity for the bacterial cell wall. Specifically we focused our attention on Plyß, an enzyme with improved cell wall-binding ability and age-independent bactericidal activity. Although PlyPH and Plyß have dissimilar binding domains, their catalytic domains are highly homologous. We characterized the biocatalytic mechanism of Plyß by identifying the specific bonds cleaved within the cell wall peptidoglycan. Our results provide an example of the diversity of phage endolysins and the opportunity for these biocatalysts to be used for broad-based protection from bacterial pathogens.


Sujet(s)
Antibactériens/métabolisme , Bacillus anthracis/composition chimique , Bacillus anthracis/virologie , N-Glycosyl hydrolases/métabolisme , Protéines recombinantes/métabolisme , Protéines virales/métabolisme , Antibactériens/composition chimique , Antibactériens/pharmacologie , Bacillus anthracis/effets des médicaments et des substances chimiques , Bactériophages/génétique , Sites de fixation , Paroi cellulaire/composition chimique , Paroi cellulaire/effets des médicaments et des substances chimiques , Paroi cellulaire/métabolisme , Escherichia coli , N-Glycosyl hydrolases/composition chimique , N-Glycosyl hydrolases/génétique , N-Glycosyl hydrolases/pharmacologie , Liaison aux protéines , Protéines recombinantes/composition chimique , Protéines recombinantes/génétique , Protéines recombinantes/pharmacologie , Facteurs temps , Protéines virales/composition chimique , Protéines virales/génétique , Protéines virales/pharmacologie
6.
Behav Brain Res ; 183(1): 111-7, 2007 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-17624452

RÉSUMÉ

The present study investigated the effects of intracebroventricular injections of 192 IgG-saporin in 7-day-old rats on (i) ultrasound vocalizations (USVs) on postnatal day (pnd) 13 following isolation and reunion with the mother and (ii) fear conditioning on pnd 18-19 recording both freezing and other behavioural responses as well as USVs. On pnd 13 lesioned and control pups showed comparable USV baseline values; a brief reunion with the mother induced a significant increase in USVs in all rats (maternal potentiation). On pnd 18, during the fear conditioning training, 192 IgG-saporin rats emitted a lower number of USVs. On pnd 19 all rats showed a stronger conditioned response (with full inhibition of locomotion) to auditory than to contextual cues. Surprisingly, lesioned rats showed a stronger fear-conditioned response to contextual cues than controls. These results suggest that early selective removal of the cholinergic basal forebrain paradoxically enhances hippocampally dependent fear-conditioned responses on pnd 19.


Sujet(s)
Neurofibres cholinergiques/physiologie , Conditionnement classique/physiologie , Peur/physiologie , Prosencéphale/physiologie , Vocalisation animale/physiologie , Animaux , Animaux nouveau-nés , Anticorps monoclonaux/pharmacologie , Apprentissage associatif/effets des médicaments et des substances chimiques , Apprentissage associatif/physiologie , Apprentissage par évitement/effets des médicaments et des substances chimiques , Apprentissage par évitement/physiologie , Choline O-acetyltransferase/métabolisme , Agents cholinergiques/pharmacologie , Neurofibres cholinergiques/effets des médicaments et des substances chimiques , Conditionnement classique/effets des médicaments et des substances chimiques , Peur/effets des médicaments et des substances chimiques , Femelle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Immunotoxines/pharmacologie , Mâle , Séparation d'avec la mère , N-Glycosyl hydrolases/pharmacologie , Néocortex/effets des médicaments et des substances chimiques , Néocortex/métabolisme , Prosencéphale/cytologie , Prosencéphale/effets des médicaments et des substances chimiques , Répartition aléatoire , Rats , Rat Wistar , Protéines inactivant les ribosomes de type 1 , Saporines , Stress psychologique/physiopathologie , Science des ultrasons , Vocalisation animale/effets des médicaments et des substances chimiques
7.
Cancer Lett ; 256(1): 73-80, 2007 Oct 18.
Article de Anglais | MEDLINE | ID: mdl-17637501

RÉSUMÉ

Targeting tumour neovasculature using antibodies to the endothelial receptor CD105 (endoglin), is a potentially useful approach for anti-tumour therapy. We report on the preparation and the cytotoxicity of a novel immunotoxin consisting in the non-toxic type 2 ribosome-inactivating protein (RIP) nigrin b linked to the monoclonal anti-human CD105 (hCD105) antibody 44G4. The immunotoxin kills specifically mouse fibroblasts expressing the biomarker CD105 (L929-hCD105+ cells) with an IC(50) value of 6x10(-10)M while nigrin b does it at 2.4x10(-7)M. Immunofluorescence analysis indicated that the immunotoxin accumulates in a perinuclear region. In contrast, 44G4 showed a specific localization on the cell surface.


Sujet(s)
Marqueurs biologiques tumoraux/immunologie , Fibroblastes/effets des médicaments et des substances chimiques , Immunotoxines/pharmacologie , N-Glycosyl hydrolases/pharmacologie , Néovascularisation pathologique/traitement médicamenteux , Protéines végétales/pharmacologie , Inhibiteurs de la synthèse protéique/pharmacologie , Animaux , Antigènes CD/immunologie , Survie cellulaire , Cellules cultivées , Endogline , Femelle , Fibroblastes/métabolisme , Cytométrie en flux , Technique d'immunofluorescence , Humains , Souris , Souris de lignée BALB C , Néovascularisation pathologique/métabolisme , Récepteurs de surface cellulaire/immunologie , Protéines inactivant les ribosomes de type 2 , Ribosomes/effets des médicaments et des substances chimiques , Ribosomes/métabolisme , Veines ombilicales/cytologie , Veines ombilicales/effets des médicaments et des substances chimiques , Veines ombilicales/métabolisme
8.
Plant J ; 49(6): 995-1007, 2007 Mar.
Article de Anglais | MEDLINE | ID: mdl-17286798

RÉSUMÉ

Pokeweed antiviral protein (PAP) produced by pokeweed plants is a single-chain (type I) ribosome-inactivating protein (RIP) that depurinates ribosomes at the alpha-sarcin/ricin loop of the large rRNA, resulting in inhibition of translation. Unlike the type II RIPs, which have an active and a binding moiety, PAP has only the active moiety. The mechanism by which toxins without a binding moiety gain access to cytosolic ribosomes is not known. We set up yeast as a simple and genetically tractable system to investigate how PAP accesses ribosomes and showed that the mature form of PAP is targeted to the cytosol from the endomembrane system in yeast. In the present study, we performed a systematic deletion analysis to identify the signal required for transport of PAP to the cytosol. We demonstrate here that processing of the C-terminal extension and sequences at the C-terminus of the mature protein are critical for its accumulation in the cytosol. Using a series of PAP mutants, we identified the C-terminal signal and demonstrated that it is distinct from the sequences required for ribosome depurination and cytotoxicity. The C-terminal motif showed sequence similarity to type II RIPs that retrotranslocate from the endoplasmic reticulum to the cytosol. These results demonstrate that a conserved sequence at the C-terminus of a type I RIP mediates its transport to the cytosol and suggest that type I and II RIPs may use a common signal to enter the cytosol.


Sujet(s)
Transport biologique/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Purines/métabolisme , Ribosomes/effets des médicaments et des substances chimiques , Asparagine/métabolisme , Cytosol/effets des médicaments et des substances chimiques , Cytosol/métabolisme , Microsomes/effets des médicaments et des substances chimiques , Microsomes/métabolisme , N-Glycosyl hydrolases/composition chimique , Protéines végétales/composition chimique , Biosynthèse des protéines/effets des médicaments et des substances chimiques , Structure tertiaire des protéines , Protéines inactivant les ribosomes de type 1 , Ribosomes/métabolisme , Levures
9.
Blood ; 109(8): 3300-7, 2007 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-17179221

RÉSUMÉ

CD8+ cytotoxic T lymphocytes (CTLs) are important effector cells responsible for tissue destruction in several autoimmune and allograft-related diseases. To discover if pathogenic T cells could be selectively deleted, we investigated the ability of a toxin coupled to major histocompatibility complex (MHC) class I tetramers to kill antigen-specific CD8+ T cells. H2-D(b) tetramers were assembled using streptavidin conjugated to the ribosome-inactivating protein (RIP) saporin (SAP). These tetramers inhibited ribosome activity in vitro, retained the T-cell receptor (TCR)-binding specificity of their nontoxic counterparts, and were internalized by 100% of target cells, leading to cell death in 72 hours. Cytotoxicity was dependent on the tetramer dose and avidity for the T cell. A single injection of the SAP-coupled tetramer eliminated more than 75% of cognate, but not control, T cells. This work demonstrates the therapeutic potential of cytotoxic tetramers to selectively eradicate pathogenic clonotypes while leaving overall T-cell immunity intact.


Sujet(s)
Lymphocytes T CD8+/immunologie , Délétion clonale/effets des médicaments et des substances chimiques , Cytotoxines/pharmacologie , Antigènes d'histocompatibilité de classe I/pharmacologie , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Animaux , Maladies auto-immunes/traitement médicamenteux , Maladies auto-immunes/immunologie , Maladies auto-immunes/anatomopathologie , Lymphocytes T CD8+/anatomopathologie , Mort cellulaire/effets des médicaments et des substances chimiques , Cytotoxines/immunologie , Antigènes d'histocompatibilité de classe I/immunologie , Souris , Souris transgéniques , Protéines inactivant les ribosomes de type 1 , Saporines , Facteurs temps , Transplantation homologue
10.
RNA ; 12(9): 1683-92, 2006 Sep.
Article de Anglais | MEDLINE | ID: mdl-16888324

RÉSUMÉ

Ribosome-inactivating proteins, such as the pokeweed antiviral protein (PAP), inhibit translation by depurinating the conserved sarcin/ricin loop of the large ribosomal RNA. Depurinated ribosomes are unable to bind elongation factor 2, and, thus, the translocation step of the elongation cycle is inhibited. Though the consequences of depurination are well characterized, the ribosome conformation required for depurination to take place has not been described. In this report, we correlate biochemical and genetic data to conclude that pokeweed antiviral protein depurinates the sarcin/ricin loop when the A-site of the ribosomal peptidyl-transferase center is unoccupied. We show that prior incubation of ribosomes with puromycin, an analog of the 3'-terminus of aminoacyl-tRNA, inhibits both binding and depurination by PAP in a concentration-dependent manner. Expression of PAP in the yeast strain mak8-1 results in little depurination unless the cells are lysed, a process that would promote loss of aminoacyl-tRNA from the ribosome. The mak8-1 strain is known to exhibit a higher affinity for aminoacyl-tRNA compared with wild-type cells, and therefore, its ribosomes are more resistant to PAP in vivo. These data contribute to the mechanism of action of pokeweed antiviral protein; specifically, they have uncovered the ribosomal conformation required for depurination that leads to subsequent translation inhibition.


Sujet(s)
Antiviraux/pharmacologie , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Purines/métabolisme , ARN ribosomique/composition chimique , ARN de transfert aminoacylés/métabolisme , Ribosomes/effets des médicaments et des substances chimiques , Ricine/composition chimique , Agents alcoylants/pharmacologie , Sites de fixation , Relation dose-effet des médicaments , Techniques in vitro , Inhibiteurs de la synthèse protéique/pharmacologie , Puromycine/pharmacologie , ARN ribosomique/isolement et purification , Protéines inactivant les ribosomes de type 1 , Ribosomes/métabolisme , Saccharomyces cerevisiae/génétique , Saccharomyces cerevisiae/métabolisme , Sulfates organiques/pharmacologie
11.
Article de Russe | MEDLINE | ID: mdl-16869270

RÉSUMÉ

We studied influence of protein synthesis inhibitors on short-term sensitization of Helix escape reaction and potentiation cholinosensitivity in command neurons. Inhibitor of protein synthesis anisomycin does not prevent behavioral sensitization. Anisomycin and irreversible inhibitor of protein synthesis saporin change the dynamics of cholinosensitivity potentiation in command neurons. The results Suggest that investigated sensitization of Helix escape reaction does not require synthesis of new proteins.


Sujet(s)
Réaction de fuite/effets des médicaments et des substances chimiques , /effets des médicaments et des substances chimiques , Neurones efférents/physiologie , Inhibiteurs de la synthèse protéique/pharmacologie , Acétylcholine/administration et posologie , Acétylcholine/pharmacologie , Animaux , Anisomycine/administration et posologie , Anisomycine/pharmacologie , Stimulation électrique , Ganglions des invertébrés/effets des médicaments et des substances chimiques , /physiologie , Immunotoxines/administration et posologie , Immunotoxines/pharmacologie , Potentiels de membrane , N-Glycosyl hydrolases/administration et posologie , N-Glycosyl hydrolases/pharmacologie , Neurones efférents/effets des médicaments et des substances chimiques , Protéines végétales/administration et posologie , Protéines végétales/pharmacologie , Inhibiteurs de la synthèse protéique/administration et posologie , Protéines inactivant les ribosomes de type 1 , Saporines
12.
Biochem J ; 400(1): 99-104, 2006 Nov 15.
Article de Anglais | MEDLINE | ID: mdl-16831127

RÉSUMÉ

Saporin, a type I ribosome-inactivating protein produced by the soapwort plant Saponaria officinalis belongs to a multigene family that encodes its several isoforms. The saporin seed isoform 6 has significantly higher N-glycosidase and cytotoxic activities compared with the seed isoform 5, although the two have identical active sites. In the present study, we have investigated the contribution of non-conservative amino acid changes outside the active sites of these isoforms towards their differential catalytic activity. The saporin 6 residues Lys134, Leu147, Phe149, Asn162, Thr188 and Asp196 were replaced by the corresponding saporin 5 residues, Gln134, Ser147, Ser149, Asp162, Ile188 and Asn196, to generate six variants of saporin 6, K134Q, L147S, F149S, N162D, T188I and D196N. By functional characterization, we show that the change in amino acid Asn162 in saporin 6 to aspartic acid residue of saporin 5 contributes mainly to the lower catalytic activity of saporin 5 compared with saporin 6. The non-involvement of other non-conservative amino acids in the differential catalytic activity of these isoforms was confirmed with the help of the double mutations N162D/K134Q, N162D/L147S, N162D/F149S, N162D/T188I and N162D/D196N.


Sujet(s)
Substitution d'acide aminé/génétique , N-Glycosyl hydrolases/métabolisme , Protéines végétales/métabolisme , Animaux , Catalyse , Domaine catalytique/génétique , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Dichroïsme circulaire , Relation dose-effet des médicaments , Électrophorèse sur gel de polyacrylamide , Mutation/génétique , N-Glycosyl hydrolases/composition chimique , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/composition chimique , Protéines végétales/pharmacologie , Biosynthèse des protéines/effets des médicaments et des substances chimiques , Protéines recombinantes/composition chimique , Protéines recombinantes/métabolisme , Protéines inactivant les ribosomes de type 1 , Saporines
13.
Gastroenterology ; 130(7): 2155-64, 2006 Jun.
Article de Anglais | MEDLINE | ID: mdl-16762636

RÉSUMÉ

BACKGROUND & AIMS: Pain is a main complaint of patients with pancreatitis. We hypothesized that such pain is mediated through ascending pathways via the nucleus gracilis (NG) and is dependent on descending facilitatory influences from the rostral ventromedial medulla (RVM). METHODS: A rat model of persistent experimental pancreatitis was used. After establishment of pancreatitis, rats received microinjection of lidocaine in the NG or in the RVM to determine the importance of neural activity at these supraspinal sites in the expression of abdominal hypersensitivity evoked by von Frey filaments (ie, pancreatic pain). Rats also were pretreated for 28 days before induction of pancreatitis with a single RVM microinjection of dermorphin-saporin to eliminate cells that drive descending facilitation. Dynorphin content was measured in the spinal cord of pancreatitic rats and the effects of spinal antidynorphin antiserum in pancreatic pain were assessed. RESULTS: Microinjection of lidocaine into either the NG or the RVM produced a time-related reversal of pancreatitis-induced pain. Pancreatitis significantly increased thoracic spinal dynorphin content and spinal antidynorphin antiserum elicited a time-related reversal of abdominal hypersensitivity. RVM dermorphin-saporin injection prevented the maintenance, but not the expression, of pancreatitis abdominal hypersensitivity and also prevented the increase of spinal dynorphin content in animals with pancreatitis. CONCLUSIONS: Our findings suggest that descending facilitation from the RVM plays a critical role in the maintenance, but not the expression, of pancreatic pain. These results provide a novel insight into the role of descending pathways and spinal plasticity in the maintenance of visceral pain from pancreatitis.


Sujet(s)
Lidocaïne/pharmacologie , Moelle allongée/effets des médicaments et des substances chimiques , N-Glycosyl hydrolases/pharmacologie , Peptides opioïdes/pharmacologie , Douleur rebelle/traitement médicamenteux , Pancréatite/traitement médicamenteux , Animaux , Ponction-biopsie à l'aiguille , Modèles animaux de maladie humaine , Interactions médicamenteuses , Immunohistochimie , Injections rachidiennes , Mâle , N-Glycosyl hydrolases/métabolisme , Peptides opioïdes/métabolisme , Mesure de la douleur , Douleur rebelle/étiologie , Douleur rebelle/physiopathologie , Pancréatite/complications , Pancréatite/diagnostic , Rats , Rat Sprague-Dawley , Valeurs de référence , Protéines inactivant les ribosomes de type 1 , Saporines , Indice de gravité de la maladie , Nerfs spinaux/effets des médicaments et des substances chimiques
14.
Exp Hematol ; 34(6): 728-35, 2006 Jun.
Article de Anglais | MEDLINE | ID: mdl-16728277

RÉSUMÉ

OBJECTIVES: CD33 is a cell surface marker of committed myelomonocytic precursors and circulating monocytes, and is also found on acute myeloid leukemia (AML) cells. CD33 belongs to a family of sialic acid-binding cell surface proteins named Siglecs, among which there are 7 other functional CD33-related Siglecs (CD33rSiglecs). We sought to characterize the spectrum of expression of the other CD33rSiglecs on bone marrow precursors and AML cells and asked if they can potentially serve as targets for therapy. METHODS: Cell surface CD33rSiglecs were analyzed by flow cytometry. The ability of certain anti-Siglec antibodies to target toxin-mediated cell killing of Siglec-expressing cell lines was characterized and compared. RESULTS: We demonstrate that Siglecs-3, -5, -6, -7, and -9 are expressed on subsets of normal bone marrow precursors, including promonocytes and myelocytes. Furthermore, most AML (but not ALL) cells express these Siglecs. There is substantial variability in Siglec type and expression level between cases, with each having a unique "CD33rSiglec fingerprint." Individual anti-Siglec antibodies along with a saporin toxin-conjugated secondary antibody can target myelomonocytic leukemia cells for death, and targeting of multiple Siglecs improves cell killing. Cytotoxicity was further enhanced by sialidase treatment of target cells, which improves antibody binding. We also confirmed that antibody binding induced rapid internalization of Siglecs from the cell surface, which is a requirement for cell killing via saporin. CONCLUSIONS: Multiple CD33rSiglecs are expressed on normal and malignant myelomonoyctic cells. Targeting these Siglecs, possibly in combinations, could improve anti-CD33 antibody therapy or be used as an alternative to anti-CD33.


Sujet(s)
Régulation de l'expression des gènes tumoraux , Lectines/biosynthèse , Leucémie myéloïde/métabolisme , Cellules souches tumorales/métabolisme , Anticorps monoclonaux/immunologie , Anticorps monoclonaux/pharmacologie , Antigènes CD/biosynthèse , Antigènes de différenciation des myélomonocytes/biosynthèse , Antinéoplasiques d'origine végétale/pharmacologie , Mort cellulaire/effets des médicaments et des substances chimiques , Humains , Capping (immunologie)/effets des médicaments et des substances chimiques , Capping (immunologie)/immunologie , Immunotoxines/immunologie , Immunotoxines/pharmacologie , Leucémie myéloïde/traitement médicamenteux , Leucémie myéloïde/immunologie , Progéniteurs myéloïdes/immunologie , Progéniteurs myéloïdes/métabolisme , N-Glycosyl hydrolases/pharmacologie , Cellules souches tumorales/immunologie , Protéines végétales/pharmacologie , Protéines inactivant les ribosomes de type 1 , Saporines , Lectine-3 de type Ig liant l'acide sialique , Lectines liant l'acide sialique apparentées aux immunoglobulines , Cellules U937
15.
Exp Biol Med (Maywood) ; 231(4): 412-20, 2006 Apr.
Article de Anglais | MEDLINE | ID: mdl-16565437

RÉSUMÉ

Saponins are a group of plant glycosides consisting of a steroid or triterpenoid aglycone to which one or more sugar chains are attached. They exhibit cell membrane-permeabilizing properties and, thus, have been investigated for their therapeutic potential. Recently, at a non-permeabilizing concentration saponinum album from Gypsophila paniculata L. has been described to enhance the cytotoxicity of a chimeric toxin in a cell culture model. To elucidate whether this enhancing effect is also mediated by other saponins, we analyzed the ability of seven different saponins to enhance the cytotoxicity of a targeted chimeric toxin. The chimeric toxin is composed of saporin, a plant ribosome-inactivating toxin, a cleavable adapter, and human epidermal growth factor (EGF). Cytotoxicity on EGF receptor (EGFR)-bearing cells was analyzed both alone and after combined application of saponin and chimeric toxin. Only two of the tested saponins, quillajasaponin and saponinum album, enhanced cytotoxicity by more than 1,000-fold, whereas the enhancement factors of the other saponins were only approximately 10-fold. In contrast to saponinum album, quillajasaponin enhanced the cytotoxicity both on control cells lacking EGFR and on target cells, indicating that, in this case, the enhancement is not target cell receptor specific. This is also the case for some of the saponins with low enhancement factors. Saponinum album resulted in a more than 13,600-fold receptor-specific enhancement, decreasing the 50% inhibitory concentration (IC(50)) from 2.4 nM to 0.18 pM, which renders it the best option to promote saporin-3-based drug uptake while retaining specificity for the EGFR.


Sujet(s)
Récepteurs ErbB/métabolisme , Immunotoxines/pharmacologie , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Saponines/pharmacologie , Animaux , Survie cellulaire/effets des médicaments et des substances chimiques , Facteur de croissance épidermique/pharmacologie , Récepteurs ErbB/génétique , Humains , Ligands , Souris , Cellules NIH 3T3 , Préparations pharmaceutiques/métabolisme , Protéines inactivant les ribosomes de type 1 , Saponines/composition chimique , Saporines , Relation structure-activité , Transfection
16.
Life Sci ; 78(7): 694-703, 2006 Jan 11.
Article de Anglais | MEDLINE | ID: mdl-16125201

RÉSUMÉ

Hypermetabolism and anorexia are significant problems associated with major burn trauma. Recent studies have shown that hypothalamic corticotropin releasing factor (CRF) elevates metabolic rate, while neuropeptide Y (NPY) reduces it. CRF also elicits anorexia, while NPY stimulates feeding. We hypothesized that elevation of CRF and decrease of NPY may be mediators of these negative effects of burn trauma. Therefore, we assessed concentrations of CRF and NPY in hypothalamus of burned rats one, three, and twenty-one days after a 30% body surface area, full-thickness, open flame burn. In addition we determined whether a biochemical lesion of CRF receptors using 3rd ventricle injections of a saporin-CRF conjugated peptide would decrease resting energy expenditure (REE). We found a three-day period of anorexia, with REE significantly increasing three days after the burn trauma. Concentrations of NPY were increased in the PVN-containing dorsomedial region of the hypothalamus 1 and 3 days after burn trauma, but were increased further in the day 1 pair-fed rats suggesting this change was a consequence of the anorexia. Levels of CRF were decreased in the ventromedial region of the hypothalamus in day 1 and day 3 burned and PF rats. Treatment with the saporin-CRF conjugate normalized REE and reduced CRF receptor-2 density in the hypothalamus of burned rats, and blocked CRF-induced hypermetabolism in sham-burned rats. Although these results suggest a role of CRF receptors in mediating burn-induced hypermetabolism, CRF itself may not be the principle ligand, as suggested by the significant elevation of hypothalamic urocortin 15 days after burn injury.


Sujet(s)
Brûlures/métabolisme , Corticolibérine/métabolisme , Métabolisme énergétique/physiologie , Hypothalamus/métabolisme , Neuropeptide Y/métabolisme , Animaux , Anorexie/métabolisme , Brûlures/physiopathologie , Corticolibérine/pharmacologie , Modèles animaux de maladie humaine , Métabolisme énergétique/effets des médicaments et des substances chimiques , Immunotoxines/pharmacologie , Mâle , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Rats , Rat Sprague-Dawley , Protéines inactivant les ribosomes de type 1 , Saporines
17.
J Biol Chem ; 280(20): 20069-75, 2005 May 20.
Article de Anglais | MEDLINE | ID: mdl-15764597

RÉSUMÉ

Pokeweed antiviral protein (PAP) is a ribosome-inactivating protein isolated from the pokeweed plant (Phytolacca americana) that inhibits the proliferation of several plant and animal viruses. We have shown previously that PAP and nontoxic mutants of PAP can directly depurinate brome mosaic virus (BMV) RNA in vitro, resulting in reduced viral protein translation. Here we expand on these initial studies and, using a barley protoplast system, demonstrate that recombinant PAP and nontoxic mutants isolated from E. coli are able to reduce the accumulation of BMV RNAs in vivo. Pretreatment of only BMV RNA3 with PAP prior to transfection of barley protoplasts reduced the accumulation of all BMV RNAs, with a more severe effect on subgenomic RNA4 levels. Using in vitro RNA synthesis assays, we show that a depurinated template causes the BMV replicase to stall at the template nucleotide adjacent to the missing base. These results provide new insight into the antiviral mechanism of PAP, namely that PAP depurination of BMV RNA impedes both RNA replication and subgenomic RNA transcription. These novel activities are distinct from the PAP-induced reduction of viral RNA translation and represent new targets for the inhibition of viral infection.


Sujet(s)
Bromovirus/effets des médicaments et des substances chimiques , Bromovirus/physiologie , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Réplication virale/effets des médicaments et des substances chimiques , Séquence nucléotidique , Escherichia coli/génétique , Escherichia coli/métabolisme , Hordeum/effets des médicaments et des substances chimiques , Hordeum/métabolisme , Hordeum/virologie , Mutation , N-Glycosyl hydrolases/génétique , Phytolacca/composition chimique , Phytolacca/génétique , Protéines végétales/génétique , Protoplastes/effets des médicaments et des substances chimiques , Protoplastes/métabolisme , Protoplastes/virologie , ARN viral/composition chimique , ARN viral/génétique , ARN viral/métabolisme , Protéines recombinantes/génétique , Protéines recombinantes/pharmacologie , Protéines inactivant les ribosomes de type 1 , Ribosomes/effets des médicaments et des substances chimiques , Ribosomes/métabolisme , Ribosomes/virologie
18.
BMC Infect Dis ; 5: 9, 2005 Feb 22.
Article de Anglais | MEDLINE | ID: mdl-15725345

RÉSUMÉ

BACKGROUND: Others and we have previously described the potent in vivo and in vitro activity of the broad-spectrum antiviral agent PAP (Pokeweed antiviral protein) against a wide range of viruses. The purpose of the present study was to further elucidate the anti-viral spectrum of PAP by examining its effects on the survival of mice challenged with lymphocytic choriomeningitis virus (LCMV). METHODS: We examined the therapeutic effect of PAP in CBA mice inoculated with intracerebral injections of the WE54 strain of LCMV at a 1000 PFU dose level that is lethal to 100% of mice within 7-9 days. Mice were treated either with vehicle or PAP administered intraperitoneally 24 hours prior to, 1 hour prior to and 24 hours, 48 hours 72 hours and 96 hours after virus inoculation. RESULTS: PAP exhibits significant in vivo anti- LCMV activity in mice challenged intracerebrally with an otherwise invariably fatal dose of LCMV. At non-toxic dose levels, PAP significantly prolonged survival in the absence of the majority of disease-associated symptoms. The median survival time of PAP-treated mice was >21 days as opposed to 7 days median survival for the control (p = 0.0069). CONCLUSION: Our results presented herein provide unprecedented experimental evidence that PAP exhibits antiviral activity in the CNS of LCMV-infected mice.


Sujet(s)
Antiviraux/usage thérapeutique , Encéphale/virologie , Chorioméningite lymphocytaire/traitement médicamenteux , N-Glycosyl hydrolases/usage thérapeutique , Protéines végétales/usage thérapeutique , Inhibiteurs de la synthèse protéique/usage thérapeutique , Animaux , Antiviraux/pharmacologie , Encéphale/métabolisme , Modèles animaux de maladie humaine , Virus de la chorioméningite lymphocytaire/effets des médicaments et des substances chimiques , Souris , Souris de lignée CBA , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Inhibiteurs de la synthèse protéique/pharmacologie , Protéines inactivant les ribosomes de type 1
19.
J Biol Regul Homeost Agents ; 19(3-4): 145-52, 2005.
Article de Anglais | MEDLINE | ID: mdl-16602630

RÉSUMÉ

An anti-CD38 mAb (IB4) coupled to saporin-S6, a type 1 ribosome-inactivating protein (RIP), was designed for ex vivo or loco-regional therapeutical applications in myeloma and lymphoma. The ability of this immunotoxin to eliminate CD38+ cells was studied in vitro on selected CD38+ human cell lines (Raji, HBL6, L540 and CEM) and on CD38+ neoplastic cells from a Non Hodgkin Lymphoma (NHL) patient. HBL6, Raji and L540 cells resulted very sensitive to the IB4/saporin-S6 conjugate, concentrations as low as 100 pM of the immunotoxin completely inhibited protein synthesis. CD38+ neoplastic cells from the NHL patient were completely eliminated after treatment with immunotoxin at 10 nM concentration. CFU-c rescue by bone marrow precursors was maintained after exposure to the immunotoxin. These results indicate that IB4/saporin-S6 is endowed with strong and specific cytotoxic effects on selected CD38+ tumor cells lineages. Consequently, it is reasonable to propose a clinical use of the IB4/saporin-S6 for ex vivo purging of unwanted cells (e.g. depletion of contaminating neoplastic cells in aphereses obtained from G-CSF-treated patients) or for loco-regional therapies of CD38+ tumors.


Sujet(s)
Antigènes CD38/métabolisme , Tumeurs hématologiques/immunologie , Tumeurs hématologiques/thérapie , Immunotoxines/immunologie , Anticorps monoclonaux/pharmacologie , Antinéoplasiques d'origine végétale/pharmacologie , Lignée cellulaire tumorale , Séparation cellulaire , Conception de médicament , Humains , Immunotoxines/pharmacologie , Techniques in vitro , N-Glycosyl hydrolases/pharmacologie , Protéines végétales/pharmacologie , Inhibiteurs de la synthèse protéique/pharmacologie , Protéines inactivant les ribosomes de type 1 , Saporines
20.
Neurosci Lett ; 361(1-3): 232-6, 2004 May 06.
Article de Anglais | MEDLINE | ID: mdl-15135936

RÉSUMÉ

Using a conjugate of substance P and the ribosome-inactivating protein saporin, neurons expressing the neurokinin-1 receptor in lamina I of the spinal cord were targeted to determine their role in the expression of a spontaneous pain behavior following intraspinal injections of quisqualic acid in the rat. Treatment was carried out at the time of injury in order to prevent the onset of the behavior, and following onset in order to evaluate the potential clinical utility of this intervention. Treatment at the time of injury resulted in significant decreases in onset-time and severity of pain behavior, while treatment at the time of onset led to a significant reduction of the spontaneous self-directed behavior. The results suggest that the substrate for at-level pain following spinal cord injury includes a population of spinal neurons expressing the neurokinin-1 receptor in the superficial laminae of the spinal cord.


Sujet(s)
Neurotoxines/pharmacologie , Douleur/étiologie , Douleur/physiopathologie , Cellules de la corne dorsale/métabolisme , Récepteur de la neurokinine 1/métabolisme , Traumatismes de la moelle épinière/complications , Moelle spinale/physiopathologie , Animaux , Comportement animal/effets des médicaments et des substances chimiques , Comportement animal/physiologie , Modèles animaux de maladie humaine , Soins du pelage/effets des médicaments et des substances chimiques , Soins du pelage/physiologie , Immunohistochimie , Immunotoxines/pharmacologie , Immunotoxines/usage thérapeutique , N-Glycosyl hydrolases/pharmacologie , N-Glycosyl hydrolases/usage thérapeutique , Neurotoxines/usage thérapeutique , Douleur/traitement médicamenteux , Protéines végétales/pharmacologie , Protéines végétales/usage thérapeutique , Cellules de la corne dorsale/cytologie , Cellules de la corne dorsale/effets des médicaments et des substances chimiques , Rats , Récepteur de la neurokinine 1/effets des médicaments et des substances chimiques , Protéines inactivant les ribosomes de type 1 , Saporines , Automutilation/traitement médicamenteux , Automutilation/métabolisme , Automutilation/physiopathologie , Peau/innervation , Moelle spinale/effets des médicaments et des substances chimiques , Moelle spinale/métabolisme , Substance P/pharmacologie , Substance P/usage thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...